AEQUS
Aequs Limited (aequs) and IIT Dharwad Roll Out Advanced Materials R&D Ecosystem
Aequs Limited (AEQUS) partners with IIT Dharwad to launch an advanced materials R&D ecosystem, enhancing innovation in precision manufacturing.
Aequs Limited (AEQUS) has announced a strategic partnership with the Indian Institute of Technology – Dharwad (IIT-D) to establish an advanced research and development ecosystem for materials science and manufacturing innovation. This initiative aims to foster deeper industry-academia collaboration in precision-driven manufacturing domains.
Enhanced Research Capabilities
The facility, set up at the IIT-D campus, is equipped to support advanced material characterization, failure analysis, manufacturing process simulation, and optimization. This collaboration will enhance IIT Dharwad’s applied research capabilities and industry engagement, enabling Aequs to deliver cutting-edge products to its customers.
Industry-Academia Integration
The operationalization of this advanced materials R&D facility with Aequs marks an important step in strengthening industry-aligned research at IIT Dharwad. This collaboration provides students and researchers with direct exposure to real-world manufacturing challenges, while enabling meaningful contributions to high-impact industrial innovation. The center is contributing to improved product quality, enhanced reliability, reduced failure rates, and more efficient manufacturing processes — critical for high-precision industries.
In addition to research, the facility is actively conducting hands-on training programs for engineers, researchers, and students, strengthening capabilities in advanced analysis of metals and non-metals. Aequs continues to support the center through technical assessments, equipment performance monitoring, and maintenance oversight, ensuring high standards of scientific rigor and operational excellence.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aequs Limited
Aequs Limited belongs to the Industrials › Aerospace & Defense sector. Here’s a quick read on where the business and the stock stand today.
Aequs gains 44.4% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 44.4% in three months. Yet revenue grows at only 6.5% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Aequs Limited.
AEQUS
Aequs Limited Approves ₹650 Crore Equity Infusion Through Warrants
Aequs Limited (AEQUS) approves ₹650 crore equity infusion through warrants to fund aerospace and consumer capacity expansion.
Aequs Limited (AEQUS) has approved a preferential issue of up to 2,80,71,690 warrants, each convertible into one fully paid-up equity share of face value ₹10, to Mellwood Trustee Services Private Limited (Trustee of the Melligeri Private Family Foundation) (“Promoter”). This move aggregates to approximately ₹650 crore and is aimed at funding the company’s aerospace and consumer capacity expansion and supporting its borrowing program.
Significance of the Infusion
The proceeds from this infusion will fund capacity expansion across the aerospace and consumer businesses, including the development of the Hosur facility, investment in subsidiaries and joint ventures supporting that expansion, and general corporate purposes. The equity will also provide the base against which the company raises its term borrowings for the expansion. This infusion aligns the Promoter Group’s economic commitment with the company’s long-term growth plans and capital requirements.
Execution and Timeline
Of the total issue size of approximately ₹650 crore, ₹325 crore will be payable upfront upon allotment of the warrants, representing 50 per cent of the issue size, and twice the regulatory minimum. The balance will be payable upon exercise of the warrants. The warrants may be exercised within 18 months from the date of allotment. Conversion of warrants into equity shares, by making payment of balance consideration, shall take place on or before December 31, 2027. Promoter has undertaken to pay the balance consideration in full, irrespective of the market price of the company’s shares at the time of exercise.
An Extraordinary General Meeting is scheduled on Thursday, October 22, 2026, through video conferencing to seek shareholders’ approval. The detailed terms and conditions of the proposed issue, along with other relevant disclosures, will be made available to shareholders and filed with the stock exchanges in accordance with applicable laws and regulations.
Aravind Melligeri, Executive Chairman & CEO, Aequs Limited, said: “We are winning programmes faster than we had planned for, and those wins need investment ahead of the revenue they bring. This issue gives Aequs committed capital to build that capacity and the equity base to support the borrowing that goes with it. The Promoter Group is subscribing at the price as per SEBI pricing formula and paying half of it upfront — that is the measure of our confidence in what this business can deliver.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Aequs Limited
Aequs Limited belongs to the Industrials › Aerospace & Defense sector. Here’s a quick read on where the business and the stock stand today.
Aequs posts a 7.5% three-month gain, but softens in the last few weeks. Margins at 12.4% are middling — adequate but leaving the business with little buffer against cost shocks. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gives back 2.2% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock holds up despite 14.8% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Aequs Limited.
AEQUS
Aequs Limited (AEQUS) gains 5% intraday, nears resistance
Aequs Limited (NSE: AEQUS) stock moves up 5% intraday, nearing resistance at ₹253. The industrials sector stock is 1.1% away from resistance.
Aequs Limited (AEQUS) gained +5% to near resistance at ₹253 on the NSE on 13 Aug 2026. The move comes as the stock tests the 6M resistance trendline, now just 1.1% away. Aequs, a player in the aerospace and defense sector, is showing strength despite the sector’s mixed performance, indicating that today’s move may be more company-specific than a broad sector rally.
Technical setup — trendlines & DMA
From a technical perspective, Aequs is currently trading above its 6M support trendline at ₹228.15, which is 8.75% below today’s price. The stock is approaching its 6M resistance trendline at ₹253, just 1.1% away. The 50-day moving average (DMA) at ₹224.6 is above the 200-DMA at ₹172.8, signaling a bullish trend. Aequs is currently in the upper third of its 52-week range, suggesting that a significant portion of its potential upside may already be priced in.
Snapshot: ₹250.03 on 2026-08-13 (chart frozen at publication)
Fundamentals & business context
On the fundamental side, Aequs presents a mixed picture. With a revenue CAGR of 15.8% over the past 5 years but a profit CAGR of 0%, the company is growing its top line but not translating that into bottom-line growth. The -12.4% profit margin indicates thin profits, which could be a concern for value-oriented investors. Institutional ownership stands at 13.4%, suggesting that the ‘smart money’ is cautiously optimistic but not overly bullish. There was no specific NSE catalyst today, so the move appears to be driven by technical factors and overall sector sentiment.
Algorithmic scorecard
The algorithmic scorecard paints a picture of a stock that is technically strong but fundamentally weak. The strongest signals come from the bullish trend, with the 50-DMA above the 200-DMA, and the excellent year-to-date performance, which has seen the stock gain 59.1%. These indicators suggest that the stock has been accumulating strength over the past year. However, the weakest signals are the low profit margin of -12.4% and the company’s loss in the last quarter, which are red flags for fundamental investors. The negligible dividend yield of 0% also limits the income potential for yield-seeking investors.
Company outlook
Management provided an optimistic outlook for the full year, expecting 45% to 50% top-line revenue growth with a doubling of operational EBITDA. The consumer segment is expected to reach EBITDA breakeven by Q4 FY27, while the aerospace segment is targeted for 25% to 30% growth and the consumer segment for 125% to 150% growth over FY26. The company is also planning a significant capex of INR660 crores for FY27, with potential acceleration in aerospace capex, and a total capex plan of USD350 million to USD400 million from FY27 to FY31. These initiatives aim to ensure required capacity is available in line with customer timelines and to drive profitable growth in the aerospace segment.
Get all details on AEQUS — P&L, peers, shareholding and more on TradeAlone.
AEQUS
Aequs Limited (NSE: AEQUS) gains 5% intraday, extends gains
Aequs Limited (NSE: AEQUS) stock moves up 5% intraday to ₹244.01, extending gains despite 6M consolidating up trend.
Aequs Limited (AEQUS) extended gains by +5% to ₹244.01 on the NSE today, driven by post-concall momentum following the Q1FY27 earnings release. The stock remains in a consolidating uptrend, with price not yet clearing the 6-month resistance. Aequs, a player in the industrials sector specifically within aerospace and defense, saw its stock rise in a sector that has shown mixed momentum, indicating this move is more company-specific rather than a broader sector rally.
Technical setup — trendlines & DMA
The current 6-month trendline structure shows Aequs stock trading near the support floor of ₹236, which is just 3.27% below today’s price, indicating limited downside risk in the short term. Resistance is set at ₹271.3, which the stock is still 11.18% below, suggesting room for further upside if the consolidation phase continues. The 50-DMA at ₹218.4 is above the 200-DMA at ₹170.0, signaling a positive longer-term trend. The stock is currently in the upper third of its 52-week range, up 81% from its low but still 11.1% below its high, indicating that while much of the potential upside may be priced in, there is still room for growth if the positive momentum continues.
Snapshot: ₹244.01 on 2026-08-05 (chart frozen at publication)
Fundamentals & business context
Aequs’s fundamental picture shows a company with strong revenue growth but facing profitability challenges. The PE ratio is not applicable given the negative profit margins of -12.4%, despite a robust 5-year revenue CAGR of 15.8%. This suggests the market may be pricing in a potential turnaround, though current earnings do not support a high valuation. Institutional ownership stands at 13.4%, indicating a cautious but present interest from smart money. There is no new NSE catalyst today beyond the recent concall, which has driven the current stock movement.
Algorithmic scorecard
Aequs’s overall algorithmic scorecard reflects a technically strong but fundamentally weak profile. The strongest signals include the bullish trend indicated by the 50-DMA being above the 200-DMA, and the bullish sentiment shown by the volume running 2.61x heavier on up days compared to down days over the past month, pointing to systematic accumulation. On the weaker side, the negligible profit margin of -12.4% leaves the company vulnerable to further losses if costs increase, and the recent quarterly loss cautions investors about the near-term financial health of the company.
Company outlook
Aequs is navigating through a period of strong revenue growth but faces profitability challenges. On the strengths side, consolidated revenue grew 55% year-on-year, with significant increases in both aerospace and consumer segments. Operational EBITDA showed a more than three-fold sequential improvement. However, the company reported an EBITDA loss and a PAT loss for Q1 FY’27, mainly due to high depreciation, amortization, and negative cash flow from operations. The consumer segment continues to operate at a loss, though there are signs of improvement.
Management outlined an ambitious outlook for Aequs, targeting 45% to 50% top-line revenue growth for the full year with a doubling of operational EBITDA. The consumer segment is expected to reach EBITDA breakeven by Q4 FY27. Aerospace growth is targeted at 25% to 30%, while consumer growth is projected at 125% to 150% over FY26. The company plans to accelerate its aerospace capex to ensure capacity aligns with customer demand, with a planned capex of INR660 crores for FY27 and a total capex plan of USD350 million to USD400 million from FY27 to FY31. The Hosur facility expansion is set to begin operations by FY29, aiming to enhance production capabilities for engine and landing gear components.
Get all details on AEQUS — P&L, peers, shareholding and more on TradeAlone.
-
Healthcare3 days agoZydus Lifesciences Limited (zyduslife) USFDA Inspection of Pharmacovigilance Concludes with Nil Observations
-
Beverages - Brewers3 days agoSom Distilleries & Breweries Limited (sdbl): Court Judgment Clears Path for Licence Renewal
-
Solar3 days agoSwelect Energy Systems Limited Expands C&I Energy Solutions Portfolio with Rollout of SWEES EN+ Solar Hybrid Inverter Range
-
AUGMONT3 days agoAugmont Enterprises Limited (augmont) Empanelled by NSE for Promotion of Electronic Gold Receipts (EGR)
-
Healthcare21 hours agoLupin Limited (lupin) Receives Tentative FDA Approval for Apixaban Oral Suspension
-
Consumer Defensive21 hours agoRadico Khaitan Limited Expands Global Reach: Indian Luxury Whisky Brands Land in the Home of Scotch
-
Capital Markets21 hours agoIndian Energy Exchange Limited Expands Energy Markets Footprint
-
Healthcare21 hours agoSun Pharmaceutical Industries Limited (sunpharma) Secures Global Licensing for Lerodalcibep, a PCSK9 Inhibitor